Latest news with #AnimalHealth
National Business Review
2 days ago
- Business
- National Business Review
Lucidome Bio appoints board chair
Lucidome Bio has appointed agricultural technology commercialisation expert Bridgit Hawkins as chairperson, strengthening its governance bench as the company advances its breakthrough methane-reducing vaccine towards global commercial development. The company was established by AgriZeroNZ, with the support of the New Zealand Agricultural Greenhouse Gas Research Centre, the Pastoral Greenhouse Gas Research Consortium and the New Zealand Government and consolidates New Zealand's intellectual property, scientific talent and funding into a single high-growth venture. Lucidome Bio chief executive David Aitken said: 'We've built strong … foundations and are now focused on making technology breakthroughs, progressing regulatory pathways, and strengthening our commercial roadmap into the future. Bridgit has navigated this transition many times and understands how to balance bold thinking with tight execution. She is set to play a critical role in helping us move with clarity and intent.' Hawkins brings deep experience in leading technology-driven companies from early concept phase through to scale and exit. As former founder and CEO of Regen Ltd, she is currently chief sustainability officer at farm management solution company CropX. Hawkins' work has spanned startup governance, capital raising, intellectual property strategy, commercial partnerships, and measuring climate tech impact for global clients. With a master's degree in agricultural science, she has also completed executive training at Stanford University's Graduate School of Business and founded Fields of Change, an initiative focused on industry-wide solutions to systemic agricultural challenges. 'Early-stage governance is very different to conventional business-as-usual. You're dealing with high potential, limited resources, and a very fast-moving market. The skill is knowing where to focus – what truly matters – and how to use the resources you have to maximise their effect,' Hawkins explained. Hawkins said what drew her to Lucidome Bio was a rare combination of breakthrough science, a purpose-led team, and a shared sense of urgency. 'The impact potential is enormous, the science is sound, and the belief is real. Now we need to show the world we can execute.' The appointment comes as Lucidome Bio gains growing international recognition, following its selection as a 2025 global finalist at the Animal Health, Nutrition and Technology Innovation Showcase in Boston where the company's methane vaccine was recognised for its potential to transform livestock methane reduction at scale. The technology targets methanogenic archaea – the microbes in a ruminant's gut responsible for methane production – by priming the animal's immune system to generate antibodies that reduce methanogen growth through a cost-effective vaccine. The result is a practical, science-backed solution that supports emission reductions without compromising animal health or productivity. 'In many parts of the world, feed additives or high-cost delivery systems simply aren't viable. A vaccine levels the playing field – it's scalable, cost-effective, and equitable and I look forward to ensuring Lucidome Bio gains traction both locally and on the global innovation stage,' concluded Hawkins. This is supplied content and not commissioned or paid for by NBR.
Reuters
27-05-2025
- Health
- Reuters
Brazil not testing cows for bird flu despite dairy cases in US
PARIS, May 27 (Reuters) - Brazil has not yet tested cows for bird flu, despite hundreds of cases in the dairy herd in the U.S., because it is focusing on poultry outbreaks after its first confirmed case on a farm this month, the country's chief veterinarian said on Tuesday. Brazil, the world's largest chicken exporter, confirmed its first outbreak of highly pathogenic avian influenza, commonly called bird flu, on a poultry farm earlier this month, prompting bans from several major importers. Bird flu has led to the culling of hundreds of millions of poultry around the globe in the past years and affected a large number of mammals, including more than a thousand dairy cows in the United States, raising concerns it could mutate into a form transmissible between humans. "For the moment we are taking care of the poultry industry," Brazil's Chief Veterinary Officer Marcelo Mota told Reuters on the sidelines of the general session of the World Organisation for Animal Health in Paris. The cattle industry is not very big in the region and Brazil mainly breeds cows for meat, not dairy, which has proven to be more vulnerable to the virus, Mota said. "The management of the herd is different and so it's also part of our decisions at this moment not to consider the situation as a first priority," Mota said. "We don't want to raise the concerns where we don't have a problem," he added. Strong biosecurity in the past two decades and concentration along the production chain were the main reasons why Brazil did not report any bird flu outbreak on a farm before, he said. "We just realized this is a challenge for life," he said.
Cision Canada
22-05-2025
- Business
- Cision Canada
GREY WOLF ANIMAL HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
TORONTO, May 22, 2025 /CNW/ - Grey Wolf Animal Health Corp. (TSXV: WOLF) ("Grey Wolf" or the "Company"), a Canadian diversified health company, today announced financial results for the three months ended March 31, 2025. Highlights Revenue for the quarter increased year over year by 31.0% to $7.9 million. Gross profit increased year over year by 34.0% to $4.2 million for the quarter. Adjusted EBITDA 1 increased year over year by 47.4% to $1.3 million for the quarter. Launched our first innovative small animal compounded product for the management of feline infectious peritonitis in cats. "We posted a solid first quarter for both revenue and Adjusted EBITDA," said Angela Cechetto, Chief Executive Officer. Ms. Cechetto went on to say, our growth was driven by an increase in our Pharmacy business by 66.1% to $5.2 million due to an increase in sales of compounded products and the full quarter impact of the acquisition of the Compounding Pharmacy of Manitoba (CPM). Excluding the impact of CPM, we experienced organic growth of 10.8% across our animal and human pharmacy businesses." Ms. Cechetto continued, "our Animal Health business unit saw a decline in revenue for the quarter of 6.5% to $2.7 million mainly due to a decline in sales of established products and offset by an increase in commissions and new products introduced during the prior year. We continued to experience softness in the veterinary channel carrying into the first quarter; however, we remain confident in the value of our product portfolio for animal health supported by the launch of new products at the end of 2024." Key Financial Data and Comparative Results Results of Operations for the First Quarter-ended March 31, 2025 Total revenue for the three-month period ended March 31, 2025 increased 31.0% to $7.9 million over the same period in 2024. Revenue in the Pharmacy business unit increased by 66.1% to $5.2 million from $3.1 million due to an increase in sales of compounded products and the impact of the acquisition of CPM. Revenue in the Animal Health business unit decreased by 6.5% to $2.7 million from $2.9 million mainly due to a decline in sales of established products and offset by an increase in commissions and new products introduced during the prior year. Gross profits for the three-month period ended March 31, 2025 were 52.6% compared to 51.5% for the same period in 2024. Gross profits were impacted by increased margins in the Pharmacy business unit as a result of decreased material and labour costs and the impact of the CPM acquisition, offset by reduced margins in the Animal Health business unit as a result of product mix. Total expenses for the three-month period ended March 31, 2025 increased 29.3% to $3.6 million over the same period in 2024. During the three-month period, there was an increase in salary, bonus, and benefits related to operational growth and the CPM Acquisition as compared to the same period in 2024, an increase in freight expenses related to the CPM Acquisition and one-time transaction costs related to the CPM Acquisition. Adjusted EBITDA 1 was $1.3 million in the first quarter 2025 compared to $0.9 million in the same period in 2024, mainly due to decreased net income for the period after adjusting the related impacts from the CPM Acquisition on interest and accretion expenses and depreciation and amortization cost, and transaction costs specific to the period ended March 31, 2025. Cash and cash equivalents were $6.8 million at March 31, 2025 compared to $6.4 million at December 31, 2024. The Company generated cash from operations of $1.1 million, which was primarily impacted by net income for the current period offset by changes in non-cash working capital items, most significantly changes in trade and other receivables, inventories, prepaid expenses, and accounts payable and accrued liabilities. As at March 31, 2025, the Company had outstanding borrowings of $26.4 million, of which $2.1 million are current and $24.3 million are non-current. The Company repaid borrowings of $0.5 million in the quarter. The Company's debt consists of three fixed rate term loans, including a mortgage of $4.4 million secured against the CPM land and building. The Company's net debt/Adjusted EBITDA 1 ratio is approximately 2.9x (2.3x excluding real estate) using 2024 proforma Adjusted EBITDA 1 of $6.7 million. Grey Wolf's financial statements and accompanying Management Discussion and Analysis for the three months ended March 31, 2025 are available under the Company's profile on 1 Non-IFRS Measures Management uses both IFRS and Non-IFRS Measures to assess the financial and operating performance of the Company's operations. These Non-IFRS Measures are not recognized measures under IFRS, do not have a standardized meaning under IFRS and are unlikely to be comparable to similar measures presented by other companies. The Non-IFRS Measures referenced in this press release includes Adjusted EBITDA. The Company defines Adjusted EBITDA as earnings before transaction costs (including, for greater certainty, transaction costs related to the CPM Acquisition), settlement costs, interest income, interest and accretion expense, income taxes, depreciation of property and equipment, depreciation of right of use assets, amortization of intangible assets, share-based compensation, foreign exchange gains or losses and other income The Company considers Adjusted EBITDA as an additional metric in assessing business performance and an important measure of operating performance and cash flow, providing useful information to help analyze and compare profitability between companies for investors and analysts. The following table provides a summary of the differences between Grey Wolf's consolidated IFRS and Non-IFRS financial measures, which are reconciled below: EBITDA and Adjusted EBITDA About Grey Wolf Animal Health Corp. Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified health company founded by a veterinarian to bring to market a broad portfolio of products that meets the unmet needs of veterinarians, physicians and patients. The Company's strategy is to in-license, acquire or compound prescription and non-prescription products for commercialization in the animal and human health market in Canada. For additional information, please visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward Looking Statements Certain information included in this press release contains forward-looking information with the meaning of applicable Canadian securities laws. This information includes statements concerning the Company's objectives, its strategies to achieve those objectives, as well as statements with respect to management's beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking information generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "would", "expect", "intend", "estimate", "anticipate", "believe", "should", "plan", "continue", or similar expressions suggesting future outcomes or events or the negative thereof. Such forward-looking information reflects management's beliefs and is based on information currently available. All forward-looking information in this press release is qualified by the following cautionary statements. Forward-looking information necessarily involve known and unknown risks and uncertainties, which may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, assumptions may not be correct and objectives, strategic goals and priorities may not be achieved. A variety of factors, many of which are beyond the Company's control, affect the operations, performance and results of the Company and its subsidiaries, and cause actual results to differ materially from current expectations of estimated or anticipated events or results. A more detailed assessment of the risks that could cause actual results to materially differ than current expectations is contained in the Risk Factors section of Grey Wolf's Management Discussion and Analysis for the three months ended March 31, 2025. The forward-looking information included in this press release is made as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. Management undertakes no obligation, except as required by applicable law, to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. SOURCE Grey Wolf Animal Health Corp.
Yahoo
22-05-2025
- Health
- Yahoo
UK Veterinary Medicine Market Trends Analysis and Growth Forecasts Report 2025-2030: Pet and Livestock Health Initiatives, Preventive Care and Vaccinations Spur Surge in Demand
The UK Veterinary Medicine Market is projected to grow from USD 2.64 Billion in 2024 to USD 4.08 Billion by 2030, at a CAGR of 7.80%. Key growth drivers include increasing pet ownership, government initiatives, and a rise in livestock population. Discover insights on market trends, competitive landscape, and future opportunities. UK Veterinary Medicine Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "UK Veterinary Medicine Market Size, Share & Trends Analysis Report by Product (Biologics, Pharmaceutical), Animal Type (Production, Companion), Route of Administration, Distribution Channel, with Growth Forecasts, 2025-2030" report has been added to UK Veterinary Medicine Market was valued at USD 2.64 Billion in 2024, and is projected to reach USD 4.08 Billion by 2030, rising at a CAGR of 7.80% This growth can be attributed to the novel product development in veterinary medicine, the rise in livestock population and increasing pet ownership rates, and the increasing government initiatives to spread awareness about animal health. There is an increasing trend of pet adoption in the country, particularly influenced by the increasing ownership of smaller pets. According to the UK Pet Food 2024 stats, the pet dog population is estimated to be around 13.5 million, which accounts for around 36% of the households in the country owning a dog. Similarly, the pet cat population is estimated to be around 12.5 million, which accounts for around 29% of the households in the country owning a cat. This surge in pet ownership has led to greater consumer spending on veterinary medicines as pet owners are increasingly prioritizing their pets' health, resulting in higher expenditures on veterinary care, medications, and preventive treatments. As pet owners become more aware of the long-term health implications and necessary care for their pets, the demand for veterinary medicine in the country is further anticipated to addition, the increasing efforts by government and private bodies through various partnerships and initiatives to increase awareness about animal health among pet and cattle owners are further contributing to the market growth. For instance, The Animal Health and Welfare Pathway, launched in 2023, aims to enhance farm animal health and welfare in the UK through collaboration among farmers, veterinarians, and the industry. This initiative is part of the Agricultural Transition Plan, focusing on improving biosecurity, tackling antimicrobial resistance, and reducing greenhouse gas emissions from support for farmers is one of the major focuses of the pathway, offering funding for veterinary consultations, capital investments, and disease control programs. This includes grants for infrastructure improvements and initiatives to enhance stockmanship through training. The pathway also aims to stimulate market demand for higher welfare products by improving transparency and ensuring fair pricing for zoonotic diseases, which can be transmitted from animals to humans, have gained significant attention due to their potential impact on public health. This awareness drives pet owners and livestock farmers to seek preventive care and vaccinations for their animals, thereby boosting the demand for veterinary medication. Similarly, in agriculture, changing practices aimed at improving animal welfare and productivity are driving demand for veterinary interventions as farmers are increasingly adopting biosecurity measures to prevent disease outbreaks within livestock populations, thereby contributing to segment Veterinary Medicine Market Report Highlights The pharmaceutical segment accounted for the largest revenue share of 67.5% in 2024 due to its wide range of clinically approved drugs that effectively treat and prevent various animal diseases. The production animal segment dominated the market with the largest revenue share of over 58% in 2024, as livestock health is directly tied to food safety, productivity, and economic returns for farmers. The injectables segment dominated the market, with a revenue share of over 44% in 2024 due to their rapid action, high bioavailability, and effectiveness in treating a wide range of conditions. The veterinary hospitals and clinics segment dominated the market with the largest share of over 40% in 2024. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.64 Billion Forecasted Market Value (USD) by 2030 $4.08 Billion Compound Annual Growth Rate 7.8% Regions Covered United Kingdom UK Veterinary Medicine Market Variables, Trends & Scope Market Lineage Outlook Parent market outlook Related/ancillary market outlook Market driver analysis Rise in livestock population and increasing pet ownership rates Novel product development in veterinary medicine Increasing prevalence of animal diseases Strategic initiatives by key players Market restraint analysis Regulatory Challenges UK Veterinary Medicine Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis Estimated Animal Population by Key Species, 2018-2024 Regulatory Framework Product Pipeline Analysis Pricing Analysis Company Profiles Boehringer Ingelheim International GmbH. Norbrook Merck & Co., Inc. Elanco Bimeda, Inc. Zoetis UK Limited. Ceva BioZyme, Inc. Phibro Animal Health Corporation Dechra (EQT) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment UK Veterinary Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Scoop
14-05-2025
- Health
- Scoop
NZ's Methane Reducing Vaccine Selected As Global Finalist For Innovation Showcase In Boston, USA
Press Release – Lucidome Bio Lucidome Bios pioneering solution has been hailed as a potential holy grail for climate action in agriculture – a low-cost, high-impact tool that could dramatically reduce greenhouse gas emissions from livestock. New Zealand agricultural biotech company Lucidome Bio has been selected as one of just fourteen global finalists to pitch at the Animal Health, Nutrition and Technology Innovation USA event this week in Boston – a significant opportunity to showcase its world-first methane-reducing vaccine on the international stage. The Innovation Showcase is a premier global platform for breakthrough companies in animal health and agtech to present game-changing innovations to a live audience of industry leaders, investors and collaborators with attendees voting for the most promising 2025 ventures. Lucidome Bio's pioneering solution has been hailed as a potential 'holy grail' for climate action in agriculture – a low-cost, high-impact tool that could dramatically reduce greenhouse gas emissions from livestock. 'As a nation globally renowned for agricultural excellence and innovation, it's fitting that New Zealand is stepping onto the world stage with a breakthrough that could help reshape the future of farming. Lucidome Bio's selection as a global finalist is more than a recognition of scientific achievement; it's a signal that New Zealand is leading the charge in practical climate solutions for agriculture. Lucidome Bio is proud to represent the strength of Kiwi science, the power of partnership, and the potential of a vaccine that could transform farming systems around the globe,' said David Aitken, Chief Executive Officer of Lucidome Bio. How it works: microbiome meets methane Lucidome Bio's vaccine aims to trigger an animal's immune system to produce antibodies in saliva that suppress the activity of methane-producing microbes (methanogens) in the rumen. These microbes are responsible for the majority of methane emitted through livestock burps which is a significant contributor to climate change. From research to reality: bringing the vaccine to farmers Lucidome Bio was established by AgriZeroNZ, with the support of the New Zealand Agricultural Greenhouse Gas Research Centre and the New Zealand government, to accelerate the commercialisation of this breakthrough – consolidating New Zealand's intellectual property, scientific talent and funding into a single high-growth venture. The company continues to work closely with AgResearch, with leading scientists seconded into the business and providing access to research facilities. The Pastoral Greenhouse Gas Research Consortium remains a shareholder, alongside AgriZeroNZ. 'A vaccine that reduces methane would be transformative for farmers worldwide. What we're developing has the potential to fundamentally shift how livestock emissions are managed – offering farmers a practical, cost-effective tool that doesn't compromise productivity. It's a solution that works with nature, not against it. Being recognised on the global stage affirms not just the calibre of New Zealand science but the urgency and relevance of what we're building. It isn't innovation for innovation's sake – it's a critical lever for climate action in agriculture and we're proud to be leading from the front,' concludes Lucidome Bio's Chairman Bridgit Hawkins. Other finalists in the 'Production animal health showcase' category include Barnwell Bio, Flox, Fluxergy, Tribe Biotech and Verility.
